ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0202

Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors

Maria A. Lopez-Olivo1, Johncy Kachira2, Maryam Buni3, Sang Taek Kim4, Huifang Lu4, Gabrielle Duhon4, Juan Ruiz4, Clifton O. Bingham III5, Cassandra Calabrese6, Robert J. volk4 and Maria Suarez-Almazor7, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas MD Anderson Cancer Center, Texas, TX, 3MD Anderson Cancer Center, Bellaire, TX, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5Johns Hopkins University, Baltimore, MD, 6Cleveland Clinic Foundation, Cleveland Heights, OH, 7MD Anderson Cancer Center, Houston, TX

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, education, patient, Qualitative Research

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Immune checkpoint inhibitors (ICI) have been extremely successful in the treatment of various malignancies. Patients with pre-existing autoimmune disorders and cancer are at risk of developing immune-related adverse events (irAEs) and flares of their underlying disease when treated with ICI, so harms and benefits must be weighed and discussed. We conducted a patient assessment of learning needs that could enhance their decision-making on the potential use of ICI.

Methods: We individually interviewed 26 patients with cancer and concomitant autoimmune disease of whom 20 had received ICI, and 6 were candidates to receive ICI. We used a semi-structured guide to explore patient health information needs, communication issues with providers, preferred delivery methods and format for learning tools.

Results: Fifty-three percent of the patients were female, median age was 62.9 (±10.9). They had rheumatoid arthritis (47.4%), psoriasis (26.3%), Crohn’s disease (10.5%), ankylosing spondylitis (5.3%), systemic lupus erythematosus (5.3%), or ulcerative colitis (5.3%). Half of the patients (52.6%) had a demonstrable disease activity of the autoimmune disease at the time of making the decision on whether to start ICI. Most (84%) of the patients had melanoma, and at the time of the interview 68.4% had completed or discontinued the ICI. Identified health information needs included: 1) information on irAEs and flares of the autoimmune condition, 2) benefits of ICI, 3) ICI mechanism of action in the context of the autoimmune disease, 4) management for flare-ups, 5) possible reasons for stopping or modifying treatment (for cancer or autoimmune disease), 6) likelihood of autoimmune disease progression or organ damage, and 7) lifestyle changes that can be incorporated to help avoiding irAEs. The needs reported by both patients who had received ICI and those who had not yet received treatment were similar with the exception of more patients who had received ICI having more questions about cancer treatment modifications. Regarding communication with providers, patients expressed the need to better understand when to contact the provider and how to share information with other providers who were managing comorbid conditions. All patients agreed that reliable information was best delivered by their oncology provider and wished to be well-informed prior to treatment. In addition, more than half of the patients (56%) wanted information delivered in different formats. They were enthusiastic about the idea of having videos, a web application, or written information with drawings and graphs delivered through the electronic health record with links to review at home, at their own pace.

Conclusion: Patients identified several areas of health information that could help in decision-making about therapy with ICI and also highlighted the importance for communication between their various providers. Finally, they expressed interest in having educational tools that could be reviewed from their physicians to help with the final decision-making.

Disclosure Statement: This study was funded by the Rheumatology Research Foundation and the National Cancer Institute (CA237619).


Disclosures: M. Lopez-Olivo, None; J. Kachira, None; M. Buni, None; S. Kim, None; H. Lu, None; G. Duhon, None; J. Ruiz, None; C. Bingham III, AbbVie, Janssen, Pfizer, Sanofi, Bristol Myers Squibb, Eli Lilly; C. Calabrese, Sanofi, Astrazenica; R. volk, None; M. Suarez-Almazor, Eli Lilly, Pfizer, Celgene, ChemoCentryx, Gilead.

To cite this abstract in AMA style:

Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Duhon G, Ruiz J, Bingham III C, Calabrese C, volk R, Suarez-Almazor M. Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/learning-needs-assessment-for-patients-with-cancer-and-a-pre-existing-autoimmune-disease-who-are-candidates-to-receive-immune-checkpoint-inhibitors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/learning-needs-assessment-for-patients-with-cancer-and-a-pre-existing-autoimmune-disease-who-are-candidates-to-receive-immune-checkpoint-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology